1. Academic Validation
  2. Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition

Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition

  • Cell Death Dis. 2022 Jul 15;13(7):615. doi: 10.1038/s41419-022-05061-8.
Chenliang Zhang 1 Chen Huang 2 Hongwei Xia 1 Huanji Xu 2 Qiulin Tang 1 Feng Bi 3 4
Affiliations

Affiliations

  • 1 Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital of Sichuan University, Chengdu, China.
  • 2 Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
  • 3 Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital of Sichuan University, Chengdu, China. bifeng@scu.edu.cn.
  • 4 Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China. bifeng@scu.edu.cn.
Abstract

Aggresome formation is a protective cellular response to counteract Proteasome dysfunction by sequestering misfolded proteins and reducing proteotoxic stress. Autophagic degradation of the protein aggregates is considered to be a key compensating mechanism for balancing proteostasis. However, the precise role of Autophagy in Proteasome inhibition-induced aggresome biogenesis remains unclear. Herein, we demonstrate that in the early stage of Proteasome inhibition, the maturation of the autophagosome is suppressed, which facilitates aggresome formation of misfolded proteins. Proteasome inhibition-induced phosphorylation of SQSTM1 T269/S272 inhibits its autophagic receptor activity and promotes aggresome formation of misfolded proteins. Inhibiting SQSTM1 T269/S272 phosphorylation using Doramapimod aggravates Proteasome inhibitor-mediated cell damage and tumor suppression. Taken together, our data reveal a negative effect of Autophagy on aggresome biogenesis and cell damage upon Proteasome inhibition. Our study suggests a novel therapeutic intervention for Proteasome inhibitor-mediated tumor treatment.

Figures
Products